Advance in glucagon-like peptide-1 receptor agonist for obesity treatment in children and adolescents
10.3760/cma.j.issn.1673-4408.2022.06.009
- VernacularTitle:胰高血糖素样肽-1受体激动剂治疗儿童与青少年肥胖的研究进展
- Author:
Weiping DENG
1
;
Zhihao JIANG
;
Changping HU
;
Ping LUO
Author Information
1. 中南大学湘雅药学院药理学系，长沙 4100781
- Keywords:
GLP-1 receptoragonist;
Liraglutide;
Obesity;
Children
- From:
International Journal of Pediatrics
2022;49(6):393-396
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, obesity has become a global public health problem, and the incidence of obesity among children and adolescents in China has been gradually increasing.Obesity in childhood will affect the development and health of children and may lead to an increased incidence of multiple chronic diseases in adulthood.The current main strategy for weight reduction in obese children is to change their dietary habits and increase physical activity, but it is prone to relapseand has a high failure rate.Obese patients exhibit persistent hunger and lack of satiety.Glucagon-like peptide-1 receptor agonists, which suppress appetite and increase satiety, have successfully treated adult obesity with good results.This article will discuss the feasibility and safety of using glucagon-like peptide-1 receptor agonists for obesity in children and adolescents by reviewing the possible mechanisms of action of glucagon-like peptide-1 receptor agonists for weight reduction and the clinical data of glucagon-like peptide-1 receptor agonists on obesity in children and adolescents.
